Anbio Biotechnology(NNNN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $23.5M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NNNN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Anbio Biotechnology (NNNN), a Healthcare sector company. NNNN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $23.5m in revenue. Based on the latest XBRL financial filings (FY 2025), Anbio Biotechnology reports quarterly revenue of $8.6M, net income of $6.4M, an operating margin of 66.7%. Top institutional holders of NNNN by reported 13-F value include GEODE CAPITAL MANAGEMENT,, EverSource Wealth Advisors,, BNP PARIBAS FINANCIAL MARKETS, based on the most recent SEC filings. NNNN trades on the Nasdaq exchange and files with the SEC under CIK 1982708. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NNNN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Anbio Biotechnology directly from SEC EDGAR.
Revenue
FY 2025
$8.6M
Net Income
FY 2025
$6.4M
Free Cash Flow
FY 2025
$-6.7M
Operating Margin
FY 2025
66.7%
Get alerted when NNNN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Anbio Biotechnology including:
Top Institutional Holders of NNNN
GEODE CAPITAL MANAGEMENT, LLC
$661.9K25,763 shEverSource Wealth Advisors, LLC
$309.9K1,430 shBNP PARIBAS FINANCIAL MARKETS
$267.2K10,400 shMORGAN STANLEY
$188.5K7,338 shUBS Group AG
$162.8K6,339 shWELLS FARGO & COMPANY/MN
$2.6K100 shBare Financial Services, Inc
$385.0015 shRonald Blue Trust, Inc.
$128.005 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $661.9K | 25,763 |
| EverSource Wealth Advisors, LLC | $309.9K | 1,430 |
| BNP PARIBAS FINANCIAL MARKETS | $267.2K | 10,400 |
| MORGAN STANLEY | $188.5K | 7,338 |
| UBS Group AG | $162.8K | 6,339 |
| WELLS FARGO & COMPANY/MN | $2.6K | 100 |
| Bare Financial Services, Inc | $385.00 | 15 |
| Ronald Blue Trust, Inc. | $128.00 | 5 |
More Healthcare Companies
View all Healthcare →Put NNNN on your watchlist
Track score changes the day Anbio Biotechnology files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NNNN a good stock to buy?
13F Pro's AI-powered analysis of Anbio Biotechnology (NNNN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NNNN are available on the NNNN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own NNNN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NNNN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Anbio Biotechnology's investment landscape.